Bicalutamide in the Treatment of Advanced Prostatic Carcinoma

A Phase II Noncomparative Multicenter Trial Evaluating Safety, Efficacy and Long-Term Endocrine Effects of Monotherapy

Mark S. Soloway, Paul F. Schellhammer, Joseph A. Smith, Gerald W. Chodak, Nicholas J. Vogelzang, Gerard T. Kennealey

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Purpose: The safety, efficacy and pharmacokinetics of bicalutamide were investigated in 150 patients with stage D2 prostate cancer. Materials and Methods: Patients received 50 mg. bicalutamide daily in an open label multicenter North American trial. Results: The objective response rate (modified European Organization for Research in Cancer Therapy criteria) was 70 percent. Of 150 patients 59 (39 percent) met prostate specific antigen criteria for partial response, and 88 (59 percent) reached treatment failure end points and withdrew. Extent of disease was a significant predictor of response but baseline testosterone was not. Breast pain and gynecomastia developed in 76 percent and 60 percent of patients, respectively. Mean drug plasma concentration was 8,528 plus/minus 2,928 ng./ml. Conclusions: Bicalutamide (50 mg.) daily was well tolerated and efficacious. However, suboptimal effects on prostate specific antigen have led to additional trials to evaluate monotherapy at higher doses.

Original languageEnglish
Pages (from-to)2110-2114
Number of pages5
JournalThe Journal of Urology
Volume154
Issue number6
DOIs
StatePublished - Jan 1 1995
Externally publishedYes

Fingerprint

Multicenter Studies
Carcinoma
Safety
Prostate-Specific Antigen
Mastodynia
Gynecomastia
Therapeutics
Treatment Failure
Testosterone
Prostatic Neoplasms
Pharmacokinetics
bicalutamide
Research
Pharmaceutical Preparations
Neoplasms

ASJC Scopus subject areas

  • Urology

Cite this

Bicalutamide in the Treatment of Advanced Prostatic Carcinoma : A Phase II Noncomparative Multicenter Trial Evaluating Safety, Efficacy and Long-Term Endocrine Effects of Monotherapy. / Soloway, Mark S.; Schellhammer, Paul F.; Smith, Joseph A.; Chodak, Gerald W.; Vogelzang, Nicholas J.; Kennealey, Gerard T.

In: The Journal of Urology, Vol. 154, No. 6, 01.01.1995, p. 2110-2114.

Research output: Contribution to journalArticle

Soloway, Mark S. ; Schellhammer, Paul F. ; Smith, Joseph A. ; Chodak, Gerald W. ; Vogelzang, Nicholas J. ; Kennealey, Gerard T. / Bicalutamide in the Treatment of Advanced Prostatic Carcinoma : A Phase II Noncomparative Multicenter Trial Evaluating Safety, Efficacy and Long-Term Endocrine Effects of Monotherapy. In: The Journal of Urology. 1995 ; Vol. 154, No. 6. pp. 2110-2114.
@article{8f1ec601ddcc46238b02df001e0c6c6c,
title = "Bicalutamide in the Treatment of Advanced Prostatic Carcinoma: A Phase II Noncomparative Multicenter Trial Evaluating Safety, Efficacy and Long-Term Endocrine Effects of Monotherapy",
abstract = "Purpose: The safety, efficacy and pharmacokinetics of bicalutamide were investigated in 150 patients with stage D2 prostate cancer. Materials and Methods: Patients received 50 mg. bicalutamide daily in an open label multicenter North American trial. Results: The objective response rate (modified European Organization for Research in Cancer Therapy criteria) was 70 percent. Of 150 patients 59 (39 percent) met prostate specific antigen criteria for partial response, and 88 (59 percent) reached treatment failure end points and withdrew. Extent of disease was a significant predictor of response but baseline testosterone was not. Breast pain and gynecomastia developed in 76 percent and 60 percent of patients, respectively. Mean drug plasma concentration was 8,528 plus/minus 2,928 ng./ml. Conclusions: Bicalutamide (50 mg.) daily was well tolerated and efficacious. However, suboptimal effects on prostate specific antigen have led to additional trials to evaluate monotherapy at higher doses.",
author = "Soloway, {Mark S.} and Schellhammer, {Paul F.} and Smith, {Joseph A.} and Chodak, {Gerald W.} and Vogelzang, {Nicholas J.} and Kennealey, {Gerard T.}",
year = "1995",
month = "1",
day = "1",
doi = "10.1016/S0022-5347(01)66709-0",
language = "English",
volume = "154",
pages = "2110--2114",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "6",

}

TY - JOUR

T1 - Bicalutamide in the Treatment of Advanced Prostatic Carcinoma

T2 - A Phase II Noncomparative Multicenter Trial Evaluating Safety, Efficacy and Long-Term Endocrine Effects of Monotherapy

AU - Soloway, Mark S.

AU - Schellhammer, Paul F.

AU - Smith, Joseph A.

AU - Chodak, Gerald W.

AU - Vogelzang, Nicholas J.

AU - Kennealey, Gerard T.

PY - 1995/1/1

Y1 - 1995/1/1

N2 - Purpose: The safety, efficacy and pharmacokinetics of bicalutamide were investigated in 150 patients with stage D2 prostate cancer. Materials and Methods: Patients received 50 mg. bicalutamide daily in an open label multicenter North American trial. Results: The objective response rate (modified European Organization for Research in Cancer Therapy criteria) was 70 percent. Of 150 patients 59 (39 percent) met prostate specific antigen criteria for partial response, and 88 (59 percent) reached treatment failure end points and withdrew. Extent of disease was a significant predictor of response but baseline testosterone was not. Breast pain and gynecomastia developed in 76 percent and 60 percent of patients, respectively. Mean drug plasma concentration was 8,528 plus/minus 2,928 ng./ml. Conclusions: Bicalutamide (50 mg.) daily was well tolerated and efficacious. However, suboptimal effects on prostate specific antigen have led to additional trials to evaluate monotherapy at higher doses.

AB - Purpose: The safety, efficacy and pharmacokinetics of bicalutamide were investigated in 150 patients with stage D2 prostate cancer. Materials and Methods: Patients received 50 mg. bicalutamide daily in an open label multicenter North American trial. Results: The objective response rate (modified European Organization for Research in Cancer Therapy criteria) was 70 percent. Of 150 patients 59 (39 percent) met prostate specific antigen criteria for partial response, and 88 (59 percent) reached treatment failure end points and withdrew. Extent of disease was a significant predictor of response but baseline testosterone was not. Breast pain and gynecomastia developed in 76 percent and 60 percent of patients, respectively. Mean drug plasma concentration was 8,528 plus/minus 2,928 ng./ml. Conclusions: Bicalutamide (50 mg.) daily was well tolerated and efficacious. However, suboptimal effects on prostate specific antigen have led to additional trials to evaluate monotherapy at higher doses.

UR - http://www.scopus.com/inward/record.url?scp=0028786511&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028786511&partnerID=8YFLogxK

U2 - 10.1016/S0022-5347(01)66709-0

DO - 10.1016/S0022-5347(01)66709-0

M3 - Article

VL - 154

SP - 2110

EP - 2114

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 6

ER -